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Abstract: 
Disorders affecting the CNS are significantly disabling and often carry a poor prognosis of 
functional recovery. Pharmacotherapies that promote functional improvement via 
neuroregeneration have proven to be an elusive goal. Factors intrinsic to the neuronal 
microenvironment, particularly myelin-associated proteins such as Nogo-A, MAG, and OMgp, 
have been shown to be important in inhibiting such regeneration through neuronal NgR1. 
Additionally, LPA signaling through LPA1 has also shown to be important in inhibiting 
neuroregeneration through mechanisms that are currently being researched. 
It has been previously shown that application of a NgR1 decoy receptor (AA-NgR(310)ecto-Fc) 
increases sprouting below the site of the lesion in rats with spinal cord contusion injuries. 
Likewise, application of this same decoy receptor effectively disinhibited functional recovery as 
exemplified by the increase in percentage of weight-bearing rats treated with the decoy 
receptor. Noting the more ideal synthetic properties of a small molecule pharmaceutical, here 
we attempt to use a small molecule inhibitor of NgR1 to induce the in vitro regeneration of 
axons following scrape injury as well as in an in vivo model of mice with SCI. Additionally, noting 
the importance of LPA1 as shown through previous studies, we also attempt to utilize a small 
molecule inhibitor of LPA1 to promote axonal regeneration.  
Our results show that inhibition of NgR1 with the small molecule inhibitor YU-NR-008 did not 
significantly improve axonal regeneration in vitro. Application of the NgR1 inhibitor YU-NR-008 
alone showed a trend toward improved axonal regeneration, albeit insignificant (mean signal 
intensity for YU-NR-008 treated animals at 1.243 ± 0.128 vs. control 1.00 ± 0.00, p = 0.0787). 
Co-treatment with YU-NR-008 and Nogo-22 did not rescue Nogo-22-mediated inhibition of 
axonal regeneration (Nogo-22 0.771 ± 0.051 vs. Nogo-22 with YU-NR-008 at 0.801 ± 0.073). 
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Additionally, functional recovery as measured by the Basso Mouse Scale (BMS) was not 
improved with the administration of YU-NR-008 following SCI for 2 or 4 weeks (D32 BMS scores 
were 4.643 ± 0.713 (SEM) for control vs. 3.550 ± 0.669 for animals treated with YU-NR-008 for 
4 weeks). Likewise, administration of the LPA1 antagonist AM095 did not improve functional 
recovery following SCI (mean BMS at 54 days for AM095-treated animals was 3.182 ± 0.532 vs. 
5.033 ± 0.448 for vehicle-treated animals). We conclude that the tested doses of YU-NR-008 and 
AM095 were ineffective in promoting recovery in a rodent model spinal cord injury.  Additional 
studies will be needed to determine whether axonal growth was stimulated by these doses, or if 
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Spinal cord injury (SCI) is estimated to affect about 250,000-300,000 people in the United 
States, with approximately 12,000 new cases each year, primarily in young adults aged 16-30 
[1]. Causes can range from sports injuries to car accidents. Incomplete tetraplegia (indicating an 
injury at the cervical level) accounts for the most frequent neurologic status (40.6%) at 
discharge, with roughly 80% of patients still unemployed at one year post-injury [1].  
In addition to the significant functional impact on the individual, there is a substantial 
financial cost to those with SCI and society at large. Depending on the level of injury, SCI can 
cost as much as $350,000-$1,000,000 per patient in the first year alone, with a lifetime cost of 
$1 million-$4.5 million for patients, which does not include lost wages due to unemployment 
[1]. Patients who suffer from SCI thus encounter a drastic paradigm shift in level of function and 
financial stability at a time in their lives typically associated with opportunity and potential. 
Research that could improve the functional outcome of such patients is therefore much needed. 
 The facilitation of functional recovery for those with SCI, however, has proven to be an 
elusive goal. For one, post-developmental neuroplasticity is rare in the CNS, as noted as early as 
1927 by Ramon y Cajal [2, 3]. The functional reason behind such stability has been hypothesized 
to be due to the need for preservation of existing neural networks for efficient higher order 
functions [3]. Numerous mechanisms for how this might occur be have been extensively studied 
and include factors intrinsic to neurons such as GAP-43, cAMP, PTEN, mTOR, KLF4, and SOCS3 
[4]. Past research has emphasized, however, that it is not only the CNS neurons themselves that 
prohibit the type of regeneration typically seen in the PNS, but also the environment in which 
the neurons find themselves in [4, 5]. In a series of seminal studies, Aguayo et al. showed that 
CNS neurons can regenerate their axons through peripheral nerve grafts and become 
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ensheathed in Schwann cells [5]. Similarly, PNS neurons do not have the same regenerative 
capacity in a CNS glial environment, highlighting the importance of the microenvironment even 
in the presence of factors intrinsic to the neuron [5].  
A number of mechanisms have been proposed to explain the environmental 
dependence of neuroregeneration. Glial scar tissue that form in the CNS can physically block the 
normal regrowth of axons into the site of injury, with chondroitin sulfate proteoglycans (CSPGs) 
playing an important molecular role in the inhibitory process [6, 7]. Premature synapse 
formation may prevent restoration of functional neural circuitry [8]. Following the experiments 
of Aguayo et al, Savio et al showed that homogenates of CNS myelin could block growth cones 
and neurite extension in vivo, implicating oligodendrocytes and the unique CNS myelin sheath 
they form as important inhibitors of neuroregeneration [9]. Subsequent studies led to the 
discovery of many of the molecular signaling elements responsible for myelin-mediated 
inhibition of CNS regeneration, and include Nogo-A, Oligodendrocyte Myelin Glycoprotein 
(OMgp), myelin-associated glycoprotein (MAG), ephrin-B3, and Semaphorin 4D [10]. This 
molecular milieu is largely unique to CNS myelin [10]. Importantly, three of these myelin-
associated inhibitors (Nogo-A, OMgp, and MAG) have been shown to interact with the neuronal 
Nogo-66 Receptor 1 (NgR1) as well as paired-immunoglobulin like receptor B (PirB), both of 
which have been implicated in inhibition of axonal outgrowth [10, 11]. 
NgR1 is the best-studied member of a family of three related (NgR1, 2 and 3) GPI-
anchored receptors located on neurons which have been shown to participate in inhibition of 
axon growth [12]. NgR1 can be found on neuronal axons as well as pre- and post-synaptic 
locations, and is typically found co-localized with Nogo-A [13]. NgR1 knockout mice show 
enhancement of rubrospinal and raphespinal neuronal tract regrowth after injury [14]. When 
NgR1 is bound to ligand (which may include CSPGs), a complex is formed with the co-
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receptors/signal transducers LINGO-1 and p75NTR or TAJ/TROY, which—possibly via protein 
kinase C—ultimately activates the RhoA/ROCK pathway, as shown in Figure 1 [3, 12, 15-17]. 
Activation of the RhoA/ROCK pathway leads to actin regulation and concomitant growth cone 
collapse and inhibition of neurite outgrowth, thus prohibiting neuroregeneration of damaged 
neuronal processes or sprouting of fibers from intact axons [18]. Specifically, activation of the 
GTPase RhoA via binding with GTP leads to downstream activation of the Rho-associated kinases 
(ROCK) I and II (ROCK II being primarily expressed in the brain and muscle tissue) [19].  
Current understanding implicates F-actin as playing a prominent role in the extension of 
filopodiae and lamellipodiae that characterize growth cones [20, 21]. In the growing axon, F-
actin undergoes polymerization at the distal growth cone while its proximal end is 
simultaneously retracted by myosin II towards the center of the axon, exhibiting an elegantly 
balanced process whose fate depends largely on external cues [21, 22]. Although the exact 
mechanism through which the RhoA/ROCK pathway mediates growth cone collapse remains a 
subject of study, growth cone collapse tends to halt axon extension and may lead to axonal 
retraction [20]. ROCK has been shown to be implicated in shutting down F-actin polymerization 
at the distal growth cone, and may also mediate axonal retraction by promoting the formation 
of F-bundles of F-actin, with retraction of the axon mediated by the action of myosin II through 
such newly formed bundles [21]. ROCK has been shown to be directly implicated in activation of 
myosin II via phosphorylation of regulatory myosin light chain regions [21].  In addition, ROCK 
prevents the dephosphorylation of the myosin light chain (and thus facilitates continued 
activation) via phosphorylation of the myosin binding subunit that anchors protein phosphatase 
1 (also known as myosin light chain phosphatase, MLCP) to myosin [22]. Thus, inhibiting NgR1-
mediated RhoA/ROCK activation represents a promising target to allow for facilitation of axonal 
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regrowth. Importantly, NgR1 has also been implicated in stabilizing the anatomy of the 
developing brain and limiting plasticity, likely through similar mechanisms [23]. 
Among the known ligands for NgR1, Nogo-A appears to have the most well-studied, 
functionally significant role in NgR1-mediated neuronal outgrowth inhibition. Following SCI, 
Nogo-A knockout mice showed improved (but strain-dependent) raphespinal and corticospinal 
tract regrowth, whereas OMgp and MAG knockout mice did not [10, 24-26]. Interestingly, triple 
knockout of Nogo-A, MAG, and OMgp did not promote functional recovery as measured by grid 
walk test when compared to wild type mice following lateral hemisection [26]. 
Nogo-A, also known as Reticulon-4A is the largest member of the Nogo family, and the 
only isoform naturally found in myelin [10, 27]. It is a 200kD protein composed of a C terminal, 
two transmembrane domains, and an extracellular N terminal [27]. Following CNS injury, Nogo-
A expression follows a predictable temporal expression pattern: At first, expression is 
downregulated as compared to baseline. Then, at 7 days post-injury, Nogo-A expression shoots 
up to roughly twice that of baseline levels [28]. While full-length Nogo-A is typically found in CNS 
tissue before and after damage, certain segments have been implicated in mediating its 
inhibitory effects: A 66 amino acid loop (Nogo-66) as well as the amino terminus itself have both 
been implicated in inhibition of axonal regeneration, although the amino terminus works 
through disruption of integrin function rather than via NgR1 [10, 28-30].  
Various methods have been attempted to restore function following CNS injury, 
including neural bypass, stem cell implantation, each undergoing active research with varying 
degrees of success [2, 31, 32]. Given the importance of NgR1-mediated inhibition via Nogo-A 
and other MAIs, however, it is conceivable that functional recovery can be mediated by 
pharmacologically facilitating regeneration of the injured axons, or, perhaps, forming new 
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collaterals from uninjured neurons [33, 34]. Indeed, this pathway has been extensively targeted 
in our own laboratory and in others [18, 33-35]. Inhibition of downstream RhoA/ROCK can help 
disinhibit myelin-mediated inhibition, but may have unintended inhibitory effects on neuronal 
motility [33]. Antibodies that target Nogo and a peptide NgR antagonist, while effective, only 
inhibit the interaction of Nogo and not OMgp or MAG and have unknown anti-myelin effects 
[15]. Perhaps the most potent inhibition of the NgR1 pathway has been demonstrated via 
intrathecal administration of the Nogo decoy receptor NgR(310)ecto-Fc following dorsal 
hemisection of the spinal cord , which was shown to enhance the growth of CST fibers in a 
functionally significant manner Figure 2 [33]. Rats so treated showed functional recovery as 
measured by improved locomotion that correlated with histological evidence of sprouting of 
axons of the corticospinal and raphespinal tracts, findings that led to testing of the agent in 
primates [15]. It is with the understanding of the significance of this pathway that a small 
molecule inhibitor of the interaction of MAIs and NgR1—with its ease of synthesis, potential for 
manipulation of solubility, potential for biologic stability, and lower cost of production—was 
sought. 
A number of methods were employed by our laboratory to find a small molecule 
inhibitor of the MAI/NgR1 interaction. High throughput screening with functional assays 
measured neurite outgrowth and revealed a number of promising molecules, but it was in silico 
screening—whereby the docking on the NgR1 of roughly 2,000,000 small molecules is tested 
based on biochemical and physical properties—that yielded a molecule known as YU-NR-008 
that showed perhaps the most promise. A DELFIA assay testing the ability of YU-NR-008 to 
inhibit the binding of NoGo-66 to NgR1 (as represented by the analog decoy receptor 
NgR(310)ecto-Fc noted above) revealed that the compound shows dose-dependent inhibition, 
with the IC50 in a reasonable range (roughly 1µM). Further studies performed by Levi Smith, PhD 
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showed that the compound could be administered intraperitoneally and reach steady-state 
levels that were pharmacologically significant (unpublished). 
Neuroplasticity is broadly defined as “changes in neuronal structure and function, 
including synaptic changes as well as modifications in neural pathways” [36]. It follows, then, 
that neuronal plasticity is not just confined to circumstances where neuronal processes are 
injured and must regenerate, but also to instances where more subtle neuronal changes may be 
evident, such as in normal anatomic development as well as in learning [23, 37]. Indeed, similar 
mechanisms involving NgR1-mediated signaling are responsible for the subtle changes found in 
development as in robust neuroregeneration [23]. Neuroanatomical plasticity in development 
(as measured by turnover of dendritic spines and axonal varicosities) is normally stabilized in 
mice at age 45 days, but ngr-/- mice maintain an adolescent-like plasticity through 180 days 
[23]. Conditional deletion of floxed ngr1 also restores dendritic spine turnover to adolescent 
levels [23].  
Perhaps in a more nuanced manner, NgR1 signaling has also been implicated in 
experimental learning paradigms [37]. The location of NgR1 at synapses—aside from axons, 
where their presence suggests a role in axonal regrowth—suggests an additional role in synaptic 
plasticity, which is also important in learning [13, 38, 39]. Recent experiments showed that 
antibody-mediated blocking of Nogo-A/NgR1 signaling increased long term potentiation (LTP) 
induced by stimulation of horizontal cortical fibers [40]. Intrathecal administration of a Nogo-A 
blocking antibody led to increased dendritic spine density as well as more effective learning of a 
novel pellet-grasping task [40]. Thus, NgR1 signaling has been implicated in a spectrum of 
behavioral paradigms requiring varying degrees of neuroplasticity. One such paradigm, fear 
conditioning and extinction, represents a rapid, functionally important method of testing 
pharmacologically-mediated interruption of Nogo-A/NgR1 signaling. 
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Fear conditioning is a classic experimental model whereby a neutral stimulus (e.g. a 
tone) is paired with an aversive stimulus (e.g. electrical shock) with the eventual outcome that 
the neutral stimulus is experienced as aversive [41]. Fear conditioning thus follows a 
classical/Pavlovian conditioning paradigm, the neuroanatomical basis of which has been well-
studied [41]. Following fear conditioning, the conditioned stimulus can be provided without the 
aversive, unconditioned stimulus, leading to a decreased fear response [42]. This process is 
called fear extinction, whereby memory erasure of a learned associated can effectively occur 
[43]. Learned fears are much more readily extinguished in rodents still in their developmental 
stage, but fears in adults tend to be much more difficult to “erase” (likely due to CSPGs 
organized into structural CNS elements known as perineuronal nets) [43]. Experiments by Akbik 
et al have shown that ngr-/- mice display a phenotype more similar to juvenile mice as 
compared to wild type [23].  Ngr-/- mice experience more rapid extinction than wild type 
(although, interestingly, no significant difference was noted in initial conditioning) [23]. 
Following fear extinction, previously learned fears can be recovered through retraining, typically 
at a rate faster than in mice who have not undergone an initial conditioning/extinction protocol 
[37]. Recently, Bhagat et al also showed that ngr-/- mice recover previously learned fears at a 
rate similar to wild type mice who had never been conditioned [37]. Results were similar for 
conditional flox-mediated deletion of ngr [37].  
The experimental design for fear extinction and retrieval requires 10 days in total, which 
is ideal for a study that could test the pharmacologic inhibition of a small molecule inhibitor of 
NgR1 signaling in an effort to promote neuroplasticity. Indeed, preliminary studies using YU-NR-
008 showed that while mice treated with 30mg/kg/12hr starting from the second day showed a 
similar rate of extinction vs. control (with YU-NR-008-treated animals showing an insignificant 
trend towards a more rapid rate of recovery), mice treated with the drug showed a significant 
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decrease in fear recovery vs. control as measured by percentage of mice showing the fear 
response (unpublished; Figure 3). Given these promising results, a series of experiments were 
devised that would employ YN-NR-008 towards the purpose of disinhibiting axonal regeneration 
in both an in vitro neuronal injury model and in vivo model of SCI. These experiments are 
described in this thesis.  
AM095  
Efforts to promote neuroregeneration of damaged neurons have been complimented by 
attempts at minimizing the damage to the CNS that occurs following injury, also called 
neuroprotection [44]. Injury to tissue can occur via direct mechanical damage as well as via the 
cascade of physiologic responses that occur following the primary injury [44]. Inflammation in 
the CNS may also be prolonged, further exacerbating the initial damage to the spinal cord [45]. 
Interestingly, a more robust inflammatory response occurs in the spinal cord than in the brain 
[46]. Glial scarring, as mentioned above, can impede functional recovery in mammalian species 
[6, 7, 47]. The CNS is shielded from typical systemic immune responses by the blood-brain 
barrier, and the inflammatory cascade in the CNS is uniquely different from other organ 
systems, in spite of production of cytokines similar to those organ systems (e.g. IL-1β and TNFα) 
[45, 48, 49].  Microglia are native to the CNS immune cell milieu but other cells like 
macrophages and (less often) neutrophils may be recruited to the area [50].  
Given the prohibitive role of secondary injury in functional recovery, approaches that 
seek to target the inflammatory response and protect the CNS from an overly ambitious 
immune response have been attempted, with limited success [50]. Corticosteroids like 
methylprednisolone show only modest benefit, and carry the risk of secondary complications 
[50]. Ibuprofen  has been shown to promote corticospinal and raphespinal sprouting after spinal 
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cord injury [10]. However, this effect has been shown to be mediated through RhoA/ROCK 
signaling rather than strictly through the drug’s anti-inflammatory properties [10]. In fact, there 
are elements of the immune response that are important for functional recovery [50]. When 
neutrophils—thought to be toxic to CNS tissue due to their release of elastase and reactive 
oxygen species—are depleted by Ly6G/Gr-1 antibodies, less white matter is spared and worse 
functional outcomes ensue [51]. It is thought that these negative effects may be mediated 
through a decrease in factors important for normal wound healing, including bone morphogenic 
proteins (BMP), vascular endothelial growth factors (VEGF), and neurotrophic factors (NTF) as 
well as slowed astrocytic reactivity (which is normally associated with a wound healing 
response) [51]. In addition, certain subsets of immature myeloid immune cells—called myeloid-
derived suppressor cells (MDSC), which are also Gr-1+—may play a suppressive role in inhibiting 
T cell responses [50]. Notably, the depletion of Gr-1+ monocytes leads to less robust functional 
recovery in mice with SCI, and Gr-1+ monocytes recruited from outside of the blood-brain barrier 
appear to be necessary for normal functional recovery following SCI [52]. Intriguingly, 
macrophages of the M2 phenotype have been shown to increased neurite outgrowth as 
opposed to their M1 counterparts [50]. It is evident, then, that the immune response is a 
sophisticated network of events, some with positive effects towards functional healing, and 
others that do not benefit functional recovery. A nuanced approach is thus required in targeting 
the immune response towards the goal of functional recovery.   
 Within the network of immune interactions taking place following SCI, the targeting of 
one pathway has shown increasing promise. Lysophosphatidic acid (LPA) is a ubiquitous 
bioactive lipid that takes part in cell proliferation and migration, cytokine and chemokine 
release, and prevention of apoptosis [53, 54]. LPA mediates its effects through at least six 7-
transmembrane, heterotrimeric G protein-coupled receptors, LPA1-6 [53]. Cells of the CNS 
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microenvironment express different receptors, with neurons generally expressing LPA1 and—
more abundantly—LPA2; astrocytes expressing LPA1 and LPA5, with upregulation of LPA1 and 
LPA2 following SCI; LPA1 and LPA3 expressed in microglia, the latter of which is upregulated in a 
model of neuroinflammation; and on oligodendrocytes, both LPA1 and LPA3 are expressed [55]. 
LPA levels have been shown to increase following SCI, and exogenous LPA exposure has been 
shown to cause demyelination, likely through interactions with LPA1 on microglia [54]. Thus, 
LPA-mediated signaling represents an intriguing target with the goal of mediating secondary 
damage due to neuroinflammation. 
Recently, Santos-Nogueira et al showed that, in addition to being upregulated following 
SCI, the inhibition of LPA1 with a selective antagonist known as AM095 prevents the 
demyelination otherwise seen with exogenous administration of LPA [54]. AM095 is a potent 
LPA1-selective antagonist (with IC50 values less than 1µM) that has high oral bioavailability, a 
half-life of 1.5 hours, and has been shown to be well-tolerated in rats and dogs [56]. Prior 
experiments performed by Swaney et al in 2011 showed that AM095 decreased pathologic 
bleomycin-induced pulmonary fibrosis as well as renal fibrosis following ureteral obstruction in 
multiple animal models, but did not affect normal wound healing [56]. Recently, Santos-
Nogueira et al also showed that AM095 (administered orally 1hr post-SCI and subsequently 
every 12 hours at 30mg/kg for one week) promotes functional recovery of mice following SCI, as 
measured by a standardized motor test, the Basso Mouse Scale (BMS) [44]. Interestingly, 
AM095 did not affect microglia counts or infiltration of macrophages [44]. An inhibition of 
demyelination was seen with the treatment, but little neuronal sparing was noted [44].  
Interestingly, the LPA/LPA receptor pathway is also implicated in neurite retraction—
LPA4, for one, can exert its effects through the Rho/ROCK pathway, as can LPA1 [53, 54, 57]. LPA 
is also present in the developing brain, with receptor expression following a predictable time 
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course [55]. In addition, the expression of lpar1, the gene responsible for LPA1 expression, was 
found to be significantly downregulated in sprouting neurons following a corticospinal tract 
lesion (pyramidotomy) (Fink et al, submitted abstract). The importance of the role of LPA1 in 
axonal regeneration was further highlighted when animals received the LPA1 antagonist AM095 
following a pyramidotomy lesion and were found to exhibit significantly enhanced sprouting of 
neurons into the contralateral ventral horn (Fink et al, submitted abstract). Furthermore, those 
animals that were treated with AM095 exhibited a greater degree of functional recovery than 
controls as measured by a grid-walking test (Fink et al, submitted abstract). It is thus intriguing 
to consider that interfering with LPA signaling may also lead to more robust axonal regeneration 
following SCI. For our experiments, we sought to initiate AM095 administration at a later time 
and treat mice with SCI for a longer period of time in an effort to isolate neuro-regenerative 












Statement of Purpose 
Our goal was to employ small molecule antagonists of receptors known to be important in 
inhibiting sprouting of intact and injured axons for the purpose of regeneration of injured axons.  
Specifically, we hypothesized that application of a small molecule (YU-NR-008, a.k.a. “Go”) 
enhances/disinhibits axonal regeneration via an NgR1-mediated mechanism in a functionally 
significant manner. Our intent was to utilize a small molecule inhibitor for the pharmacologic 
inhibition of NgR1 towards these specific aims:  
1. Observe in vitro disinhibition of axonal regeneration upon application of Go in the 
presence of an endogenous inhibitor (NoGo-22). 
2. Observe improved recovery of function as well as rate of functional recovery in an in 
vivo model of SCI. 
Additionally, we hypothesized that administration of the LPA1 inhibitor AM095 would lead to 
improved functional recovery and rate of recovery following SCI when administered at 
30mg/kg/12hr, beginning 24 hours for a total of 20 days. This time course was chosen in an 
attempt to isolate neuroregenerative effects from neuroprotection from damage primarily 
secondary to inflammation. Specifically, we sought to observe improved recovery of function as 








In Vitro CNS Injury Model/Scrape Assay 
Cell Culture 
For our primary in vitro neuroregeneration assay, C57Bl/6 pregnant female mice with E17-E18 
embryos were sacrificed. Brains of the embryonic mice were dissected and cortical neurons 
from both hemispheres were isolated and placed into Hibernate E –CaCl2 medium (BrainBits). 
Following aspiration of medium, cortical neurons were placed into an enzyme solution 
containing Mg/Ca-free HBSS (4mL), papain (96µl), EDTA (25µl), CaCl (7.5µl), and DNAse 
(10mg/mL, 500µl) for 20-30min. of incubation. Subsequently, tissue was washed once with 10ml 
HBSS and twice with 10ml Neurobasal-A medium with additives (500ml Neurobasal medium 
(NB-A), 5ml of 1% Pen-strep, 5ml Na-Pyruvate (1mM), 5ml GlutaMax (2mM), and 10ml B-27 
supplement). The tissue was then homogenized by repeated pipetting and was subsequently 
filtered through a 40µm cell strainer. This cell solution was then diluted 38:1in Neurobasal-A 
solution (noting that one pup brain provides confluent coverage of neurons for 3 plates) and 
was subsequently placed into the 60 central wells of a 96-well plate at a volume of 200µl/well, 
with the outermost wells containing sterile water. Each plate was divided into four quadrants to 
represent each condition, and each experiment was repeated 4 times (on 4 different plates), 
allowing for rotating of the quadrants to allow for greater power and to avoid potential bias 
introduced via location in incubator.  The cells were allowed to grow in culture for 7-16 days, 
depending on the experiment, with medium changed at 7 days. Scrape injury was performed at 
7-16 days using a 96-well special scraping tool made for this purpose (V&P Scientific) and 150µl 
of medium was removed from each well. Subsequently, 50µl of relevant condition was placed: 
Control containing a solution of 8% DMSO, 46% PEG 400, and 46% of 10% cyclodextrin in H2O at 
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a concentration of 100nM-1µM in Neurobasal-A medium; Nogo-22 (10nM-300nM); 1mg Go 
dissolved in the same solution used for control at concentrations of 100nM-10µM; and Go with 
Nogo-22 at indicated concentrations).  
Nogo-22 is a 22kDa isolated fragment of Nogo-A that contains three important inhibitory 
components: Nogo-66, Nogo-A-24, and Nogo-C39 [58]. It has been shown to be a more potent 
suppressor of axon regeneration than Nogo-66 alone in previous experiments performed by 
Huebner et al [58]. We thus sought to use Nogo-22 in an effort to test competitive inhibition 
with our small molecule inhibitor YU-NR-008.  
Neurons were allowed to sit for 3-7 days with relevant condition, and were subsequently fixed 
using 4% PFA in PBS, made permeable with 0.1% Triton, and then stained using anti-βIII 
microtubulin overnight. Subsequently, Alexa Flour-488 donkey anti-mouse antibody (Life 
Technologies) was applied along with DAPI (Cell Signaling Technologies) and rhodamine 
phalloidin (Life Technologies) for imaging. 
Imaging   
Images were obtained via fluorescent microscopy using ImageExpress Micro XL. Images were 
then cropped using ImageJ (NIH) to capture only the area of axonal regeneration. Subsequently, 
individual images were run through a MatLab (R2012b) program that records Alexa-Flour 488 
(green) signal above a preset threshold intensity. Typically, each experimental condition was 
repeated on four plates, with quadrants rotated to account for any discrepancy in location on 
the plate and in the incubator. Means for each quadrant were normalized to the mean of the 
vehicle treated neurons given substantial variation from plate to plate based on previous 
experience in the laboratory, making it difficult to compare from one plate to another. Means 
were calculated and compiled using Excel (Microsoft), and the means were then used as data 
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points in the final analysis for statistical significance via 2-way ANOVA using statistics computing 
software (GraphPad Prism 6).  
In vivo mouse SCI model   
Surgery  
11-12 week old female C57Bl/6 animals were placed under anesthesia using 1-5% isoflurane. 
Location for the incision and subsequent T7-T9 laminectomy was determined by using the 
vertebra prominens as an anatomical landmark in mice for T10. Following the incision, 
paraspinous muscles were dissected using small scissors to reveal the spinous process of T7-T9 
and associated lamina. Microscissors were used to perform a bilateral laminectomy to reveal 
the spinal cord. Curved iridectomy scissors were then used to perform a dorsal hemisection to a 
depth of 1.1mm. The incision site was subsequently closed using an intramuscular suture 
followed by 3-4 skin sutures (4-0 Vicryl; Ethicon). Pain relief was provided using buprenorphine. 
Penicillin was used for antibiotic prophylaxis. 
Post-operative animal care was performed through twice daily bladder expression for the first 7-
14 days, followed by once daily thereafter. Routine post-operative care was performed and 
animals were regularly weighed following the procedures. 
Treatment Protocols  
Go injections (3-6mg/mL as a suspension in sunflower oil) and control (sunflower oil alone) 




AM095 was suspended in normal (0.9%) saline with 1% DMSO to a final concentration of 
3mg/mL. To ensure adequate dissolution, the mixture was sonicated for 10 minute intervals 3 
times at 37oC. Treatment began 24 hours after dorsal hemisection for 20 days.  
Assessment of functional recovery 
To assess for functional recovery, hind leg movements were assessed according to the Basso 
Mouse Scale (BMS) [59]. Animals were observed for BMS first on D3 post-spinal cord injury (SCI), 
and thereafter once weekly. Animals were randomized to control and treatment groups based 
on the initial D3 BMS measurement.  
For AM095-treated animals, BMS measurement were performed roughly 24 hours post-
operatively, on D3, and subsequently every 7-8 days. Control and treatment groups were 
randomized according to baseline BMS on D1. 
Corticospinal tract tracer injection 
On D38 of all experiments, animals were brought to the surgery room and anesthetized with 1-
5% isoflurane as above. Anesthetized animals were affixed to a stereotaxis apparatus, and, 
following scalp incision, 5 burr holes were drilled using a micro-drill (Foredom) on the R lateral 
side of bregma (burr hole 1 at 2mm lateral, 1mm anterior to the frontal suture; burr hole 2 at 
1mm lateral, 0.5-1mm posterior to the frontal suture; burr hole 3 at 3mm lateral, 1mm posterior 
to the frontal suture; burr hole 4 at 1mm directly posterior to burr hole 2; burr hole 5 at 1mm 
directly posterior to burr hole 3. A 30G needle was used to puncture the skull at the areas of the 
burr holes, taking care not to puncture the dura. A stabilized microsyringe with a pump 
controller (World Precision Instruments) was used to inject 75nl 10% BDA 0.7mm deep to the 
dura at a rate of 75nl/min at each burr hole site.  
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Alternatively, a craniectomy was performed using a micro-drill (Foredom) starting 1mm lateral 
to bregma and posterior to the frontal suture and extending 2mm anteriorly; then laterally to 
3mm lateral to bregma, 1mm anterior to the frontal suture; from that point, drilling was 
extended 2mm directly posteriorly; drilling was then continued in the medial direction for 2mm 
to reach the original drilling site. Forceps were used to remove the incised skull and to expose 
the dura mater. 5 BDA injections were administered in a similar orientation to the burr hole 
protocol. Animals were subsequently sutured and were placed on a heating pad for recovery 
following cessation of anesthesia. Ampicillin and buprenorphine in LR were administered per 
protocol.  
Histologic Analysis 
On D56 animals were euthanized and subsequently perfused via intracardiac perfusion with 
chilled normal saline for 3-5 minutes for exsanguination and subsequently with chilled 4% PFA in 
PBS for 3-5 minutes. Spinal cords were then obtained and stored in 4% PFA in PBS for future 
analysis and imaging. 
Experimenters 
The initial dorsal hemisections for the 2 week-Go treated SCI experiments were primarily 
performed by Xingxing Wang, MD. The first surgery and harvesting of E18 mouse cortical 
neurons was performed by Yuichi Sekine, MD.  Aside from these, the following experiments and 
data analysis were primarily performed by Hiam Naiditch under the guidance of Yuichi Sekine, 
PhD (cell culture/Scrape Assay) and Xingxing Wang, MD (animal surgeries and tissue preparation 
for forthcoming histological analysis). Basso Mouse Scale measurements require more than one 
observer. Special thanks to Tomoko Sekine-Komo, Maria Dell’Anno, PhD, Yuichi Sekine, PhD and 




Nogo-22 inhibits axonal regeneration 
Nogo-22 is a 22kDa fragment of Nogo-A that contains the three inhibitory regions Nogo-66, 
Nogo-A-24, and Nogo-C39. Nogo-22 has been previously shown to inhibit the outgrowth of 
neurons more potently than Nogo-66 alone [58]. Our experiments confirmed that Nogo-22 
significantly inhibits the outgrowth of neurites when applied to neurons at 7 DIV for 3, 5, and 7 
days of treatment. Figure 4a is a representative image showing Nogo-22 mediated inhibition on 
axonal regeneration into the scrape area vs. control. As shown in Figure 4b, Nogo-22 potently 
inhibits axonal regeneration when applied for three (mean fluorescent antibody signal intensity 
0.788 ± 0.043 for Nogo-22-treated (n=16) and 1.00±0.00 (n=20) for vehicle-treated (data are 
normalized), five (0.683±0.123 for Nogo-22 (n=16) and 1.00±0.00 for vehicle; n=16) and seven 
days (0.416±0.049 for Nogo-22 (n=8) and 1.00±0.00 for vehicle treated; n=8). Data represent 
relative intensity of signal normalized to vehicle from a fluorescent antibody to β-III tubulin 
(found in axons) and are displayed as means with standard errors of the mean and were 
analyzed by 2-Way ANOVA using GraphPad Prism 6 statistical software. 
Importantly, neurons kept in culture with Nogo-22 for longer led to a greater degree of 
inhibition, as shown in Figure 4b. The importance of time of application of Nogo-22 has been 
previously shown in a similar experiment performed by Huebner et al, and suggests the role of 
Nogo-A/NgR1 signaling in development of stable neural networks in the CNS [58]. Our 
experiments suggest additionally that the amount of time of application of Nogo-22 may allow 
for greater Nogo-22-mediated inhibition, presumably also via the upregulation of NgR1.   
YU-NR-008/Go is non-toxic to neurons 
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As shown in Figure 5a, following culture of neurons for 7DIV, application of 100nM of the NgR1 
inhibitor Go for treatment for 3, 5 and 7 days shows a trend towards improvement in axonal 
regeneration as compared to control, although this trend is not significant. Similarly, increasing 
the concentration of Go to 1µM and applying to cultures at 7DIV for 3 days for varying days in 
treatment did not yield significant improvement in axonal regeneration. As shown in Figure 5b, 
at 3 days of treatment with 100nM Go, Go-treated neurons showed a relative β-III tubulin signal 
of 1.296 ± 0.150 (n=16) vs. vehicle treated (1.000 ± 0.000; n=12). At 5 days, Go-treated neurons 
were 1.290 ± 0.140 (n=12) vs. vehicle treated (1.000 ± 0.000; n=8). At 7 days, Go-treated 
neurons were 1.357 ± 0.271 (n=4) vs. 1.000 ± 0.000 for vehicle-treated (n=4).  
Considering the potential role of YU-NR-008/Go as a competitive antagonist, we sought to 
increase the concentration of Go to override Nogo-22 mediated inhibition. We also sought to 
determine the effects of this concentration on neurons treated only with Go as compared to 
control. As shown in Figure 5b, application of 1µ Go for 3 days of treatment beginning at 7DIV 
yielded a mean signal intensity of 1.140 ± 0.184 (n=8) vs. vehicle (1.000 ± 0.000; n=8). At 5 days, 
Go-treated showed a mean signal intensity of 1.417 ± 0.167 (n=12) vs. control (1.000 ± 0.000; 
n=8). At 7 days, Go-treated were 1.054 ± 0.253 (n=4) vs. vehicle (1.000 ± 0.000; n=4). Thus, 
increasing the concentration of Go does not appear to increase axonal regeneration in the 
absence of exogenous Nogo-22.  
Noting that expression of NgR1 increases with the age of the neurons (Figure 6c, courtesy of 
Yuichi Sekine, PhD), we sought to optimize the experiment by increasing days in vitro prior to 
application of Go. Similar to the above results, following culture of neurons for 13DIV, 
application of 1μM Go for a 3-day treatment promotes a trend towards improvement in axonal 
regeneration as compared to control (fold change of 1.243 ± 0.128 (SEM) for Go-treated vs. 1.00 
± 0.00 for vehicle), although this trend is not significant (p=0.0787) (Figure 6a).  Likewise, 
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treatment of neurons cultured for 16DIV did not yield improvement in axonal regeneration as 
compared to control. Figure 5c is a representative image showing the increase in axonal 
regeneration with Go application.  
Treatment with the NgR1 inhibitor YU-NR-008/Go does not rescue Nogo-22-mediated 
inhibition of axonal regeneration 
We sought to model the interaction of endogenous MAIs with NgR1 in the presence of the small 
molecule NgR1 inhibitor YU-NR-008/Go. To test whether Go inhibited binding of Nogo-22, we 
employed varying concentrations of the drug and the surrogate ligand for varying number of 
days.  
As shown in Figure 6a, co-administration of 100nM Nogo-22 and 100nM Go at 7DIV did not lead 
to reversal of Nogo-22-mediated inhibition of axonal regeneration. For instance, at 7 days of 
treatment, neurons co-treated with Go and Nogo-22 (0.484 ± 0.066; n=4) and Nogo-22 alone 
(0.480 ± 0.082) experienced a similar inhibition of axonal regeneration. 
Likewise, increasing the number of days in an attempt to account for increasing NgR1 expression 
as development progresses did not lead to a reversal of Nogo-22 mediated inhibition of axonal 
recovery. As shown in Figure 6b, o-administration of 300nM Nogo-22 and 1µM Go at 13DIV did 
not lead to reversal of Nogo-22-mediated inhibition of axonal regeneration. As expected, 
treatment with Nogo-22 yields significant inhibition (Nogo-22 0.771± 0.051 (SEM) vs. control 
1.00 ± 0.00, p=0.00434). Co-treatment with Go and Nogo-22 did not lead to rescue of Nogo-22-
mediated inhibition of axonal regeneration (Nogo-22 0.771 ± 0.051 vs. Nogo-22 with Go 0.801 
± 0.073).   
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In an attempt to assess whether Go worked as a competitive inhibitor in the presence of Nogo-
22, we also sought to use varying ratios of Nogo-22 to Go (See Figure 6d). Previous experiments 
have shown that a concentration of 310nM is sufficient in inducing a noticeable difference in 
axon regeneration, but as little as 1nM may induce growth cone collapse [58]. As shown in 
Figure 6c, the application of Go in the presence of 200nM Nogo-22 did not allow for rescue of 
Nogo-22-mediated inhibition of neuroregeneration (0.771 ± 0.051 for Nogo-22 vs. 0.801 ± 0.073, 
p=0.746). Figure 6e shows a representative image showing the difference in regeneration 
following treatment with 100nM Go vs. control. Thus, treatment with YU-NR-008/Go alone does 
not appear to antagonize Nogo-22-mediated inhibition of axonal regeneration. 
2-week and 4-week treatment with Go does not appear to improve functional recovery 
following SCI 
For the in vivo studies, as shown in Figure 7d, 2-week treatment with Go at 30mg/kg/12hr did 
not appear to promote functional recovery following dorsal hemisection as measured by the 
Basso Mouse Scale (BMS). For instance, at D39 mean BMS for Go-treated animals was 2.40 ± 
0.46 (n=10) vs. 1.667 ± 0.479 for control (n=9).  
To determine whether increases the time of exposure to drug following SCI would promote 
neuroregeneration, the experiment was repeated, this time with treatment for 4 weeks. As 
shown in Figure 7e, 4-week treatment with Go at 30mg/kg/12hr did not appear to promote 
functional CNS recovery following dorsal hemisection as measured by the BMS. For example, the 
differences between D32 BMS scores (4.643 ± 0.713 (SEM) for control vs. 3.550 ± 0.669 for Go-
treated animals) or D39 (4.071 ± 0.561 (control) vs. 3.35 ± 0.624) were not significant. Data 
represent means with SEM; statistical analysis was performed using GraphPad Prism and 
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employed 2-way ANOVA. Figures 7a, b, and c provide cross-sectional and sagittal views 
portraying the nature of the dorsal hemisection lesion [60, 61]. 
Administration of the LPA1 antagonist AM095 does not appear to contribute to functional 
recovery via axonal sprouting 
We sought to test the hypothesis of whether the application of the LPA1 antagonist AM095 
would rescue LPA-mediated inhibition if AM095 were applied after the inflammatory cascade 
had begun in an attempt to isolate the neuroregenerative effects of AM095. As seen in Figure 
8a, initiating treatment with AM095 at 24 hours post-SCI for 20 days did not appear to improve 
functional recovery as compared to control. For example, mean BMS at 54 days for AM095-
treated animals was 3.182 ± 0.532 (n=11) vs. 5.033 ± 0.448 for vehicle-treated animals (n=15).   
Given the potential for skewed data with a disproportionate number of abnormally high 
baseline performers (as in D3 baseline, measured after randomization), BMS data was analyzed 
excluding those animals who scored higher than a baseline BMS of 3. Similar to above, 
functional recovery was not improved with administration of AM095 24 hours post-SCI. For 
instance, mean BMS at 54 days for AM095-treated animals was 2.90 ± 0.499 (n=10) vs. 4.545 ± 
0.455 for vehicle-treated animals (n=11). Data represent means with SEM; statistical analysis 








In conclusion, application of small molecule inhibitor of NgR1 YU-NR-008/Go did not appear to 
be effective in our in vitro assays or in an in vivo model of SCI. In our in vitro assays, we noted 
that Nogo-22 potently suppresses axonal regeneration, and this suppression was not rescued 
with the co-administration of Go (Fig. 4 and 6). The inhibition of axonal regeneration with Nogo-
22 was expected, as noted in previous studies [58]. What has not been previously studied, 
however, was the effect of increasing time of exposure to Nogo-22. We show here that 
increasing the time of exposure to Nogo-22 increases inhibition of axonal regeneration (Fig. 4). It 
is unlikely that the interaction of Nogo-22 with NgR1 takes a full 7 days to reach equilibrium. 
Rather, in line with previous experiments that have shown an increasing capacity for Nogo-22 to 
suppress axonal regeneration at a greater number of days in research, it is likely that increased 
suppression is due to increased expression of NgR1 as cultured neurons progress through 
development, as noted by Huebner et al [58]. Thus, older cultures are presumably more 
sensitive to Nogo-22 than younger cultures [58].  
It is notable that Go mediates improvement—albeit non-significant—when applied to neurons 
without exogenous Nogo-22 (Fig. 5). It is possible that this might be due to blockade of low 
levels of endogenous Nogo present in the cultures. Additionally, given the high potency of Nogo-
22, it may be that, if Go were to be co-administered with lower potency Nogo-66, a reversal of 
inhibition could be seen.  Importantly, Go-mediated improvement without the co-administration 
of Nogo-22 was not enhanced by increasing the number of days in culture. Theoretically, as 
NgR1 expression increases, so should Go-mediated disinhibition of axonal regeneration. 
However, increasing the number of days that Go stays in culture also renders the compound 
susceptible to the effects of time in the non-lipophilic culture medium. The lack of statistical 
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significance in our findings may suggest toxicity, precipitation of our highly lipophilic compound 
out of solution, or small molecule oligomerization, thus rendering it inactive for inhibition of 
NgR1. Of note, the precipitation of Go out of solution limited prior experiments in our 
laboratory (data not published). (It should also be noted that some time prior to 
experimentation was devoted to determining an effective mixture into which the YU-NR-008 
could remain dissolved in solution, highlighting the compounds lipophilic nature.) Alternatively, 
other non-NgR1 related mechanisms may play an important role, indicating that inhibition of 
the Nogo-A/NgR1 interaction may not be sufficient in disinhibiting axonal regeneration. 
Importantly, the trend in disinhibition of axonal regeneration seen with Go-treated neurons is 
not seen with Go co-applied with Nogo-22, indicating a lack of rescue Nogo-22-mediated 
inhibition of axonal regeneration. A Western blot performed to confirm the veracity of our 
preparation of Nogo-22 showed slight differences in band intensity as compared to original 
preparations of Nogo-22 (data not shown). Interestingly, the lack of disinhibition was also noted 
at higher doses (up to 50µM Go—data not shown), which also suggests that the binding of our 
Nogo-22 preparation may be irreversible; thus, the application of a small molecule inhibitor in 
an attempt to competitively antagonize Nogo-22 binding may be futile with such an 
experimental model. As suggested above, it would be particularly interesting to compare the 
inhibition resulting from Nogo-22 administration with that mediated by Nogo-66. The original 
DELFIA assay produced an IC50 for Nogo-66 rather than Nogo-22. Importantly, Nogo-22 has been 
shown to induce growth cone collapse in E13 DRG neurons with a potency that is more than ten 
times that of Nogo-66, which suggests that Nogo-22 may bind with higher affinity to NgR1 than 
Nogo-66 [56]. It would therefore be interesting and important to study the competitive 
interaction of Go directly with Nogo-22, and to determine whether Nogo-22 or Nogo-66 
accurately reflects the inhibition mediated by ligands endogenous to the neuronal environment. 
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Importantly, administration of the ROCK inhibitor Y27632 led to reversal to Nogo-22 mediated 
inhibition of axonal regeneration of cortical neurons, indicating that the ineffectiveness of YU-
NR-008 in the presence of Nogo-22 likely reflects NgR1-related competition upstream from 
ROCK [58]. Thus, it is possible that Nogo-22 has such a slow off rate that it is essentially an 
irreversible inhibitor of NgR1. It is also possible that our agent YU-NR-008/Go may bind in a 
different location than Nogo-22. Go may thus inhibit binding of Nogo-66, but not Nogo-22 via its 
potentially unique binding site. Our hope is that future work might elucidate such 
pharmacodynamic properties of Nogo-22 and YU-NR-008.  
In our behavioral studies, we did not notice any significant difference between the Go-treated 
and control animals when animals were treated for 2 or 4 weeks (Fig. 7). Following our two 
week experiment, many of the animals in either of the groups suffered complications such as 
hydrocephalus and urinary tract infections, thus confounding our results. Likewise, following 
animal sacrifice, material with the appearance of precipitated compound was noted in the 
peritoneum, near the site of injection. Excluding animals with ill appearance and hydrocephalus 
from the final data analysis yielded similar results, although by doing so the number of animals 
in the control group may be deemed insufficient to yield reliable results (data not shown). 
Importantly, surgical technique may have also introduced a significant degree of variability from 
animal to animal. For animals treated for 4 weeks, one important factor that might explain the 
lack of functional improvement was a similar loss of animals from the control group at later time 
courses due to illness. Interestingly, most of the animals lost from the control group (4 out of 5) 
had a baseline BMS score of 0-0.5 on D3 (with the fifth animal scoring 1.0 on D3). In contrast, 
there were three animals lost or excluded from the Go-treated group, with baseline scores of 0, 
0.5, and 3.5, respectively. As the animals were initially divided into treatment groups of equal 
average baseline scores, it is evident that the loss of these animals led to a selective advantage 
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of the control-treated vs. Go-treated animals. This likely introduced selection or attrition bias 
into our final analysis. Additionally, this may explain the trend to improved recovery, albeit 
insignificant, that is seen with the control group vs. the Go-treated animals.  
The discrepancy in our results from those obtained by Wang et al through administration of the 
Nogo decoy receptor NgR1(310)ecto-Fc may be also be explained by the direct intrathecal 
administration of the latter, which—in contrast to intraperitoneal administration—may have 
facilitated more localized regenerative effects at the spinal cord [62]. Similarly, in contrast to the 
spinal cord contusion injury employed by Wang et al, our own experiments employed a partial 
hemisection, which—while ideal for studying neuroregeneration—can lack consistency from one 
animal to another [63].  
With regards to the original fear extinction model which prompted further interest, the short 
period of treatment may have helped avoid the development of precipitation of compound in 
the abdomen following intraperitoneal injection (Fig. 3; unpublished). The discrepancy with our 
experiment also suggests that while the compound YU-NR-008 might be ideal with regards to 
experience-mediated effects that rely on plasticity of intact neurons, it may not be effective 
when more robust neuroregeneration is needed [10]. Similarly, in contrast to the relatively 
static expression of Nogo-A in the adult CNS, it is also important to consider the time-dependent 
expression of Nogo-A in the CNS following injury. The effect of time on Nogo-A expression has 
been extensively studied with varying results, although a more recent, perhaps more 
comprehensive study verified that Nogo-A mRNA expression initially falls below baseline values 
and reach a trough at 3 days post-SCI, indicating a permissive environment for axonal 
regeneration shortly after injury [28]. Soon after, however, Nogo-A expression shoots up to 
levels that are almost twice that of baseline, indicating that this period of permissive growth is 
short-lived [28]. Similar results were seen with immunohistochemistry and Western blot analysis 
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of tissue. Elevated levels of Nogo-A continued to be higher than baseline at two weeks post-
injury [28]. Importantly, our behavioral experiments using YU-NR-008 attempted to follow a 
time course that relied on a three-day period of post-operative recovery and thus an accurate 
baseline BMS score that would allow for accurate randomization, with an initial application at 3 
days post injury and a steady state reached at D4-D5. Given the above findings by Wang et al, 
the administration of a small molecule inhibitor of NgR1 may be optimally timed for 3-7 days 
post-SCI, which coincided with our experimental method [28]. It is possible, however, that the 
activity of other ligands might exhibit different expression patterns following injury. For 
example, OMgp does not show the same initial decrease as Nogo-A does following injury; 
rather, its expression increases steadily through 28 days following injury [64]. Importantly, NgR1 
expression appears to follow a trend similar to Nogo-A following CNS injury, although the only 
significant difference seen vs. sham is an increase in mRNA expression 2 weeks post-injury, 
highlighting the relative stability of NgR1 expression—and thus capacity for RhoA/ROCK-
mediated inhibition of axonal regeneration—immediately after injury [65]. 
It is intriguing to consider the role of the downstream effector pathway, RhoA/ROCK, in 
mediating inhibition of axon growth. It has been shown that in addition to suppressing axonal 
regeneration, the RhoA/ROCK pathway is important for maintaining polarity of growth cones 
[66]. Thus—similar to the importance of NgR1 in the adult human to ensure efficient and stable 
neuronal networks—NgR1 may be vital for guidance of new growth cones towards their 
appropriate targets. In light of this, while blocking NgR1 signaling may promote the propagation 
of growth cones shortly after administration of YU-NR-008, the activation of an additional 
mechanism (e.g. via external cues) might be necessary to guide newly established growth cones 
towards their appropriate destination [66]. Notably, NgR1 knockouts do exhibit a phenotype of 
more robust, functionally significant axonal recovery [67]. However, this may be accounted for 
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through redundant pathways that provide cues for growth cone polarity.  Likewise, the 
effectiveness of a decoy receptor for Nogo-A also allows for the retention of NgR1 on damaged 
neurons, indicating that external cues relevant for polarity might act with greater nuance to 
allow for maintenance of effective growth cone polarity [68]. It is also possible that YU-NR-008 
might not inhibit NgR1 potently enough to mirror the axonal regeneration seen with application 
of the decoy Nogo receptor. Histologic analysis of spinal cord tissue is forthcoming, and should 
show whether NgR1 led to any axonal regeneration in spite of insufficient evidence for 
functional recovery.  
AM095  
Our experiments noted that treatment with AM095 did not enhance functional recovery 
following SCI as compared to control. This is in contrast to previous experiments performed by 
Santos-Nogueira et al, where a similar dosage of AM095 was used but with treatment begun at 
an earlier time [44]. Santos-Nogueira et al noted that LPA levels are significantly increased from 
baseline starting at least 6 hours following injury [44]. Importantly, LPA and its receptors are 
believed to be important mediators in the inflammatory process that contributes to secondary 
damage in the spinal cord. The earlier this process can be inhibited, the better. Indeed, such a 
thought process appears to have been followed with regards to choosing an ideal time to 
initiate treatment: AM095 was first administered 1 hour after SCI [44]. In addition to its 
neuroprotective effects, however, LPA has been directly implicated in activating growth cone 
collapse via the RhoA/ROCK pathway. This pathway leads to the phosphorylation and thus 
inactivation of the myosin light chain phosphatase, thus allowing for the myosin II/actin network 
to contract [22].  Interestingly, Santos-Nogueira et al showed that LPA1 was implicated in 
promoting demyelination in the CNS following injury [54]. A recent experiment showed that LPA 
also exerts its demyelinating effects through the RhoA/ROCK pathway, at least in the PNS [69]. 
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Thus, in performing our experiments, our goal was to attempt to isolate, in part, the 
neuroregenerative effects of inhibiting the LPA/LPA1 pathway. Although histological analysis 
needs to be performed to assess whether axon regeneration of existing neurons occurred in our 
experiment, the lack of a behavioral phenotype may point to a role for the otherwise ubiquitous 
LPA that is more important in mediating secondary injury and demyelination rather than growth 
cone collapse. However, a few important distinctions between our experiments warrant 
attention: 
Whereas the experiments performed by Santos-Nogueira et al employed an impactor device to 
produce spinal cord contusions, our experiments employed the dorsal hemisection model [44]. 
Spinal cord contusion performed with validated impactor devices can limit injury variability, 
whereas in our experiments the experimenter’s surgical technique may have introduced a 
significant degree of variability from animal to animal [63]. In addition, based on prior 
experimentation in our laboratory, it is difficult to obtain an accurate baseline BMS is difficult to 
achieve until 3-7 days of days following SCI. Accurate baselines are needed for adequate 
randomization. Animals that are scoring at a BMS of 2 the first post-operative day are likely to 
not have as severe an injury as animals scoring at 0 or 1. Thus, it is possible that the animals 
randomized to the treatment group were more severely injured (or even that the animals 
receiving treatment in the behavioral study performed by Santos-Nogueira et al were not as 
severely injured) [44]. It is also interesting to consider that neuroprotection through inhibiting 
inflammation may play a more important role in the contusion model, whereas functional 
recovery following a surgically-induced cord hemisection may rely more on axonal regeneration. 
Further experiments are thus required to truly disambiguate the functional significance of 
AM095 treatment following SCI.    
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Our experiments also appeared to show different results from those reported by Fink et al 
following AM095 treatment of animals who underwent unilateral medullary pyramidotomies 
(abstract submitted). In their experiments, AM095 was initially administered at the same dose 
(30mg/kg/12h) but at 5 hours post-pyramidotomy. This initial administration precedes the 
measured rise in LPA noted by Santos-Nogueira at 6 hours, which supports a neuroprotective 
rather than neuroregenerative role for AM095 [54]. Additionally, other experimenters have 
noted that the pyramidotomy is an ideal method for assessing sprouting from intact neurons 
[70]. Whether our animals exhibited sprouting from neurons left intact following hemisection 
remains to be seen on histological analysis, but it has been noted that functional recovery 
following medullary pyramidotomy may operate via a different pathway, i.e. 1may require a 
more robust neuroregenerative effect [71]. Thus, while AM095 might be ideal from a 
neuroprotective standpoint, its effectiveness along a spectrum of neural growth that spans from 
plasticity to robust regeneration of severed axons may be limited to sprouting of intact axons. 
Further studies that would experimentally initiate treatment of AM095 at a later time course 
might help to further elucidate the primary pathway by which the agent acts. 
Importantly, while our results—taken with other experiments—suggest a neuroprotective 
rather than neuroregenerative role for AM095, it is important to emphasize that it can be 
difficult to delineate between the two phenomena. Neuroprotection effectively inhibits the 
formation of scar tissue, which—acting via CSPGs—has been shown to inhibit 
neuroregeneration [10, 72]. Thus, while there is evidence to suggest that contralateral sprouting 
in animals who received pyramidotomies may occur following administration of AM095, without 
altering the time course of treatment, it may be difficult to attribute such sprouting to 
neuroregeneration. Given the potential effect of neuroprotection, it is interesting to consider 
the potentially additive effect of administering AM095 (or other LPA1 antagonist) immediately 
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following spinal cord injury and following this with administration of an NgR1 antagonist at a 
time that coincides with Nogo-A expression post-SCI, e.g. 2-3 days following injury [28]. In this 
way, one could inhibit the inflammatory cascade that is likely detrimental to neurons and 
associated myelin while disinhibiting the outgrowth of axons to allow for functional recovery. 
Likewise, if inhibition of the LPA1 pathway was confirmed to facilitate axonal regeneration (as 
suggested by previous research), the additive effects of inhibiting LPA1 and NgR1 signaling may 
provide for a more robust cellular and functional recovery than either compound alone.  Further 
research may help to elucidate the interaction of these two proposed mechanisms of CNS 
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Figure References and Legends 
Figure 1.  
 
Figure 1. NgR1 signaling pathway. (Figure from JY Lee et al 2013). Nogo-A, Oligodendrocyte 
Myelin Glycoprotein (OMgp), myelin-associated glycoprotein (MAG) have been shown to 
interact with the neuronal Nogo-66 Receptor 1 (NgR1) as well as paired-immunoglobulin like 
receptor B (PirB), both of which have been implicated in inhibition of axonal outgrowth. When 
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NgR1 is bound to ligand (which may include CSPGs), a complex is formed with the co-
receptors/signal transducers LINGO-1 and p75NTR or TAJ/TROY, which—possibly via protein 
kinase C—ultimately activates the RhoA/ROCK pathway. Activation of the RhoA/ROCK pathway 
leads to actin regulation and concomitant growth cone collapse and inhibition of neurite 
outgrowth, thus prohibiting neuroregeneration of damaged neuronal processes or sprouting of 



















Figure 2. The Nogo decoy receptor NgR(310)ecto-Fc enhances the growth of CST fibers in a 
functionally significant manner. (Images courtesy of Lin et al 2004) A An example of two camera 
lucida drawings from rat spinal cords following biotinylated dextran amine (BDA) injections into 
the sensorimotor cortex of the brain show that NgR(310)ecto-Fc treated rats exhibit greater 
sprouting caudal to the site of the lesion (indicated by the black arrow). B Intrathecal 
administration of NgR(310)ecto-Fc promotes functional recovery following dorsal hemisection 
as measured by the Basso, Beattie and Bresnahan Locomotor Score for rats. 7-9 rats per group 
received dorsal overhemisection with subsequent intrathecal administration of vehicle or 
NgR(310)ecto-Fc. BBB at 21d was 15.5 ± 0.2 ( p < 0.01) for NgR(310)ecto-Fc treated animals and 
12.5 ± 0.9 for control. This experiment was repeated two more times (once at a different 
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institution) with similar significant results. C Control animals are noted to have significantly 
shorter strides with wider stance at 4 weeks following injury as compared to NgR(310)ecto-Fc 
treated animals or animals without SCI. D Rats treated with NgR(310)ecto-Fc have notably less 




















Figure 3. YU-NR-008, a small molecule Inhibitor of NgR1, shows promise in a rodent model of 
neuroplasticity.  (Figure and data courtesy of Kalp, Bhagat et al, unpublished). A Crystal structure 
as elucidated by J. Lauren et al showing residues critical for binding of all three primary myelin-
associated inhibitors (MAI; i.e. MAG, OMgp, and Nogo-A) shown in red, residues required for 
some, but not all MAI in yellow, and non-essential residues shown in turquoise. The black box 
was used for in silico compound screening  [74] . B The biochemical structure of YU-NR-008, also 
known as “Go”. C A DELFIA assay showing the dose response curve for YU-NR-008-mediated 
antagonism of Nogo-66 binding to immobilized NgR(310)ecto-Fc. D One day following fear 
conditioning, mice received 30 mg/kg/12h YU-NR-008 intraperitoneally (n=10) or vehicle (n=10) 
and showed similar rates of fear extinction. E However, mice treated with the drug showed a 
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significant decrease in fear recovery vs. control as measured by percentage of mice showing the 
fear response. Data represent the means with SEM for vehicle treated (n=19), 6 mg/kg/12h YU-
NR-008 (n=8) or 30 mg/kg/12h YU-NR-008 (n=20) as measured by ANOVA with Bonferroni 




















Figure 4. Nogo-22 is a potent inhibitor of axonal regeneration. A is a representative image 
showing Nogo-22 mediated inhibition on axonal regeneration into the scrape area vs. control. B 
As expected, Nogo-22 potently inhibits axonal regeneration when applied for three 
(0.788±0.043 for Nogo-22-treated (n=16) and 1.00±0.00 (n=20) for vehicle-treated (data are 
normalized), five (0.683±0.123 for Nogo-22 (n=16) and 1.00±0.00 for vehicle; n=16) and seven 
days (0.416±0.049 for Nogo-22 (n=8) and 1.00±0.00 for vehicle treated; n=8). Data represent 
relative intensity of signal normalized to vehicle from a fluorescent antibody to β-III tubulin 
(found in axons) and are displayed as means with standard errors of the mean and were 









Figure 5.  
 
Figure 5. Go is non-toxic to neurons. A 100nM of YU-NR-008 treatment of cortical neurons at 
7DIV for 3, 5 and 7 days shows a trend towards improvement in axonal regeneration as 
compared to control, although this trend is not significant. At 3 days of treatment, Go-treated 
neurons showed a relative β-III tubulin signal of 1.296±0.150 (n=16) vs. vehicle treated 
(1.000±0.000; n=12). At 5 days, Go-treated neurons were 1.290±0.140 (n=12) vs. vehicle treated 
(1.000±0.000; n=8). At 7 days, Go-treated neurons were 1.357±0.271 (n=4) vs. 1.000±0.000 for 
vehicle-treated (n=4). B Similarly, increasing the concentration of Go to 1µM and applying to 
cultures at 7DIV for varying days of treatment did not yield significant improvement in axonal 
regeneration. At 3 days of treatment, treatment with 1µM Go yielded a mean signal intensity of 
1.140±0.184 (n=8) vs. vehicle (1.000±0.000; n=8). At 5 days, Go-treated showed a mean signal 
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intensity of 1.417±0.167 (n=12) vs. control (1.000±0.000; n=8). At 7 days, Go-treated were 
1.054±0.253 (n=4) vs. vehicle (1.000±0.000; n=4). Data represent relative intensity of signal from 
a fluorescent antibody to β-III tubulin (found in axons), normalized to vehicle, and are displayed 
as means with standard errors of the mean and were analyzed by 2-Way ANOVA using 
GraphPad Prism statistical software. C is a representative image showing the increase in axonal 

















Figure 6.  
 
Figure 6. Go does not rescue Nogo-22-mediated inhibition of axonal regeneration. A As shown, 
treatment with 100nM Go at 3, 5, and 7 days does not rescue inhibition of axonal regeneration 
vs. control, although a trend exists (green bar). However, co-treatment with Go and Nogo-22 
does not appear to rescue Nogo-22-mediated inhibition of axonal regeneration (blue bar). For 
example, at 7 days of treatment, neurons co-treated with Go and Nogo-22 (0.484 ± 0.066; n=4) 
and Nogo-22 alone (0.480 ± 0.082) experienced a similar inhibition of axonal regeneration. B 3-
day treatment with Go at 13 DIV. Treatment with Nogo-22 yields significant inhibition (Nogo-22 
0.771± 0.051 (SEM) vs. control 1.00 ± 0.00, p=0.00434). Application of the NgR1 inhibitor Go 
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on its own showed a trend toward improved axonal regeneration, albeit insignificant (Go 1.243 
± 0.128 vs. control 1.00 ± 0.00, p = 0.0787). Co-treatment with Go and Nogo-22 did not rescue 
Nogo-22-mediated inhibition of axonal regeneration (Nogo-22 0.771 ± 0.051 vs. Nogo-22 with 
Go 0.801 ± 0.073). C Increasing the number of days in vitro to 16 followed by treatment with 
Go does shows similar results: 0.820±0.033 (n=3) for Nogo-22 alone (red column) vs. 
0.899±0.089 (n=3) for Go-treated (green column) vs. 0.737±0.046 for Go with Nogo-22 (n=3) vs. 
1.000±0.000 (n=3) for vehicle-treated. Data represent relative intensity of signal from a 
fluorescent antibody to β-III tubulin (found in axons), normalized to vehicle-treated, and are 
displayed as means with standard errors of the mean and were analyzed by 2-Way ANOVA using 
GraphPad Prism statistical software. D A Western blot showing the rationale for attempting 
experiment optimization by increasing the number of DIV. As shown, NgR1 expression increases 
with time, although neuroregeneration becomes substantially inhibited the older neurons are 
(Figure unpublished, courtesy of Yuichi Sekine, PhD. Similar findings are noted in Huebner et al 
[58]. E A representative image showing the difference in regeneration with Nogo-22 alone vs. 












Figure 7. Treatment with Go does not promote functional recovery in spinal cord injury. A A 
representative image from Lang et al. shows a cross section of a mouse spinal cord from level 
T8, using Neurotrace (ThermoFisher Scientific) as a counterstain. The dotted line shows the area 
of intended transection using microscissors [61]. B As shown in this image from Lang et al, the 
goal of the dorsal hemisection is to transect the main CST to ensure that recovery of function is 
associated with regeneration rather than retention of main CST fibers [61]. The baseline Basso 
Mouse Scale (BMS) score affords a functional measurement of the effectiveness of the dorsal 
hemisection. C Cresyl violet- and eosin-stained section showing a representative lesion using a 
precise incision device [60]. For our experiments, microscissors were employed using a similar 
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depth of injury (0.8-1.1mm).  D Mean BMS scores for mice treated with control or NgR1 
inhibitor at D3 after dorsal hemisection. As shown, animals are divided into groups with a similar 
mean baseline score. 2-week treatment with Go at 30mg/kg/12hr did not appear to promote 
functional recovery following dorsal hemisection as measured by the BMS. For instance, at D39 
mean BMS for Go-treated animals was 2.40±0.46 (n=10) vs. 1.667±0.479 for control (n=9). 
Continuing the experiment for one more week yielded similar results (data not shown). E 4-
week treatment with Go at 30mg/kg/12hr did not appear to promote functional CNS recovery 
following dorsal hemisection. For example, the differences between D32 BMS scores (4.643 ± 
0.713 (SEM) for control vs. 3.550 ± 0.669 for Go-treated animals) or D39 (4.071 ± 0.561 
(control) vs. 3.35 ± 0.624) were not significant. Data represent means with SEM; statistical 













Figure 8.  
 
Figure 8. Treatment with AM095 starting 24 hours after spinal cord injury does not appear to 
promote functional recovery. A As shown, treatment with the LPA1 antagonist AM095 starting 24 
hours after injury did not appear to yield improvement in functional recovery as measured by 
the Basso Mouse Scale (BMS). For example, mean BMS at 54 days for AM095-treated animals 
was 3.182 ± 0.532 (n=11) vs. 5.033 ± 0.448 for vehicle-treated animals (n=15). B Given the 
potential for skewed data with a disproportionate number of abnormally high baseline 
performers (as in D3 baseline, measured after randomization), BMS data was analyzed excluding 
those animals who scored higher than a baseline BMS of 3. Similar to above, functional recovery 
was not improved with administration of AM095 24 hours post-SCI. For instance, mean BMS at 
54 days for AM095-treated animals was 2.90 ± 0.499 (n=10) vs. 4.545 ± 0.455 for vehicle-treated 
animals (n=11). Data represent means with SEM; statistical analysis was performed using 
GraPad Prism and employed 2-way ANOVA. 
 
